Analyst Ratings For Theravance Biopharma
Analysts have provided the following ratings for Theravance Biopharma (NASDAQ:TBPH) within the last quarter:
10 Biggest Price Target Changes For Thursday
Barclays boosted Adobe Inc. (NASDAQ: ADBE) price target from $660 to $740. Adobe shares rose 0.1% to $661.26 in pre-market trading.
The Daily Biotech Pulse: Leap, Phio, Silverback Among Early Movers On Oncology Conference Presentations, Aerie Slumps On Mixed Data, Axsome Commences Phase 3 Sleep Disorder Study
Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Sept. 15)
Morgan Stanley Maintains Underweight on Theravance Biopharma, Lowers Price Target to $10
Morgan Stanley analyst Vikram Purohit maintains Theravance Biopharma (NASDAQ:TBPH) with a Underweight and lowers the price target from $14 to $10.
53 Biggest Movers From Yesterday
Gainers
DICE Therapeutics, Inc. (NASDAQ: DICE) shares surged 117% to settle at $36.89 on Wednesday as the company priced its IPO at $17 per share.
HC Wainwright & Co. Maintains Buy on Theravance Biopharma, Lowers Price Target to $8
HC Wainwright & Co. analyst Douglas Tsao maintains Theravance Biopharma (NASDAQ:TBPH) with a Buy and lowers the price target from $21 to $8.
SVB Leerink Maintains Outperform on Theravance Biopharma, Lowers Price Target to $10
SVB Leerink analyst Geoffrey Porges maintains Theravance Biopharma (NASDAQ:TBPH) with a Outperform and lowers the price target from $29 to $10.
Why Are Theravance Bio Shares Plummeting Premarket Today?
Theravance Biopharma Inc (NASDAQ:TBPH) will reduce its headcount by approximately 75% (estimated 270 positions), with most of the lay off to…
